SCHEMBL3882913

SCHEMBL3882913

CN(Cc1cccc(C(=O)NCc2ccc(C(F)(F)F)cc2)c1)S(=O)(=O)c1cc2ccccc2s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LSS P48449 1/20 0.48
RAB9A P51151 2/20 0.44
LMNA P02545 1/20 0.44
MRGPRX4 Q96LA9 1/20 0.43
MAPT P10636 1/20 0.42
POLB P06746 1/20 0.42
PSMD14 O00487 1/20 0.42
STAMBP O95630 1/20 0.42
MAPK14 Q16539 1/20 0.42
SENP5 Q96HI0 1/20 0.42
SENP2 Q9HC62 1/20 0.42
SENP1 Q9P0U3 1/20 0.42
ROCK2 O75116 1/20 0.41
CNR2 P34972 1/20 0.41
MCHR1 Q99705 1/20 0.41
ALDH1A1 P00352 2/20 0.41
GAA P10253 1/20 0.41
HSD17B10 Q99714 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HDAC3 O15379 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3876863 0.89 NR1H4 (0.49) RAB9ALMNAMAPTPOLBSENP5
SCHEMBL3872970 0.88 ROCK2 (0.45) RAB9ALMNAMAPTPOLBSENP5
SCHEMBL3880937 0.87 RAB9A (0.52) RAB9ALMNAMAPTPOLBROCK2
SCHEMBL3879715 0.83 LSS (0.50) LSSRAB9ALMNAMRGPRX4MAPT
SCHEMBL3886237 0.79 TRPM8 (0.49) LMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL3879707 0.79 RAB9A (0.53) RAB9ALMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL3882723 0.78 ALDH1A1 (0.51) LMNAPOLBCNR2ALDH1A1GAA
SCHEMBL3887293 0.78 MAPT (0.49) RAB9ALMNAMAPTSENP5SENP2
SCHEMBL3881241 0.77 LSS (0.43) LSSLMNAMRGPRX4MAPTGAA
SCHEMBL3872649 0.76 ALDH1A1 (0.49) RAB9ALMNAALDH1A1HSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814846-B1 11BETA-HSD1 INHIBITORS EVOTEC AG (DE) 2009-04-08 EP disclosed
US-20090069323-A1 11beta-hsdi inhibitors EVOTEC AG (DE) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069323-A1 11beta-hsdi inhibitors HSD3B1, HSD3B2, HSD11B1 LSS 219/4885RAB9A 4300/4885LMNA 2473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.